• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Fund Review Might Change The Case For Investing In DEXUS (ASX:DXS)

    Simply Wall St·10/22/2026 16:38:57
    Listen to the news
    • DEXUS has engaged Denison Partners to review liquidity options for the Dexus Healthcare Property Fund after investors requested redemptions, including asset sales, alternative capital structures or a potential wind down of the vehicle.
    • The review highlights funding and liquidity pressure within DEXUS's healthcare platform, placing the balance between meeting redemption requests and preserving fund value under close scrutiny.
    • We will now look at how this healthcare fund review, and the potential for asset sales, could influence DEXUS's wider investment narrative.

    Scan how DEXUS handles liquidity pressure, then size up other real estate groups facing investor flows with our hand picked list of solid balance sheet and fundamentals (12 results) for comparison.

    DEXUS Investment Narrative Recap

    To own DEXUS, you need to be comfortable with a real asset platform that links a A$15.3b listed portfolio to a A$36.1b funds management arm, with earnings tied to occupancy, rents and fee income. The healthcare fund review shines a light on liquidity management rather than day to day leasing metrics. The key short term catalyst still sits in execution on developments and tenant retention, while the main risk is funding pressure as debt is not well covered by operating cash flow.

    Where this review bites is in confidence around third party capital. Persistent redemption requests across vehicles could pressure funds under management and fee revenue, especially with revenue already expected to decline by 4.7% a year over the next 3 years. If DEXUS can deal with healthcare redemptions without fire sale pricing, it may limit damage to earnings quality and perceptions of platform strength.

    The Denison Partners appointment is the announcement that matters most here. It formalises a process to deal with investors seeking cash from the Dexus Healthcare Property Fund, at a time when the wider group already relies 100% on higher risk funding sources such as external borrowings. You are effectively watching a live test of how DEXUS balances liquidity, valuation discipline and fee resilience.

    Investor trust in the platform is a major operational swing factor. Continued stress in one fund could make it harder to grow or even hold external capital, which then feeds into management fees and appetite for new projects. In contrast, clear communication, orderly asset sales and controlled gearing would align with the current narrative of high quality earnings, improving margins and a business that some models still see trading well below estimated future cash flow value.

    What The DEXUS Forecasts Are Asking You To Believe

    DEXUS' current story leans heavily on what analysts think the next few years can support, rather than what the past few years have delivered. That is especially true when you line up their healthcare fund liquidity test against the numbers embedded in consensus models.

    DEXUS' narrative projects A$952.7 million revenue and A$715.3 million earnings by 2029. This rests on analysts assuming revenue will decline 12.3% each year and an earnings increase of about A$165.3 million from A$550.0 million today.

    Analysts are effectively assuming a smaller top line but a much fatter profit pool, with margins today at 39.0% and pencilled in at 75.1% in 3 years. That combination only works if costs, financing and asset churn line up cleanly. For an investor watching the healthcare fund review, the question is how comfortably liquidity actions, including any asset disposals, fit inside those earnings ambitions rather than cutting across them.

    Current consensus points to A$715.3 million of profit, A$0.72 in earnings per share and a P/E multiple of 16.2x in 2029, compared with 12.0x today. Those figures also assume that DEXUS lifts its valuation premium above the wider AU Office REITs group, which sits at 11.6x. That is a meaningful ask in a sector still working through office demand shifts and elevated gearing.

    On top of that, analysts expect the share count to rise by 4.48% a year over the next 3 years. Extra equity can support balance sheet flexibility if funding stays tight, although it also spreads future earnings over more units. If you own DEXUS, or are comparing it with other listed property groups, the key task is to judge whether a smaller revenue base, higher margins and a richer multiple all belong in the same forecast set, given the liquidity priorities on display in the healthcare platform today.

    Uncover why DEXUS' fair value indicates a 30% potential upside to its current price, which could narrow quickly.

    ASX:DXS 1-Year Stock Price Chart
    ASX:DXS 1-Year Stock Price Chart

    Exploring Other Perspectives

    For a different angle, focus on the bullish catalyst around capital recycling. The most optimistic analysts were assuming DEXUS could reach about A$1.2b of revenue and A$1.1b of earnings by 2029, using asset partnerships and fund launches to grow. The healthcare review might reshape those expectations, so treat this as one of several viewpoints to consider.

    Explore 2 other DEXUS fair value estimates, including one that suggests as much as 46% upside from the current price!

    The Verdict Is Yours

    Don't just follow the ticker; dig into the data and build a conviction that's truly your own.

    Looking For More DEXUS-Sized Investment Ideas?

    Once you have formed a view on DEXUS, it can help to line it up against other opportunities that match your risk appetite, income goals and balance sheet comfort level. The Simply Wall St Screener lets you filter for exactly that mix so you can build a watchlist that actually reflects how you want to invest.